v3.26.1
Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Balance at the beginning at Dec. 31, 2024 $ (21,380)   $ 263,879 $ (285,259)
Balance at the beginning (in shares) at Dec. 31, 2024   3,262,000    
Issuance of common stock in the 2025 PIPE   5,213,000    
Issuance of common stock in a private placement 53,190 $ 1 53,189  
Vesting of restricted stock units   20,000    
Stock-based compensation expense 834   834  
Net (loss) income (26,970)     (26,970)
Balance at the end at Mar. 31, 2025 5,674 $ 1 317,902 (312,229)
Balance at the end (in shares) at Mar. 31, 2025   8,495,000    
Balance at the beginning at Dec. 31, 2024 (21,380)   263,879 (285,259)
Balance at the beginning (in shares) at Dec. 31, 2024   3,262,000    
Net (loss) income 12,776      
Balance at the end at Jun. 30, 2025 47,114 $ 1 319,596 (272,483)
Balance at the end (in shares) at Jun. 30, 2025   8,570    
Balance at the beginning at Mar. 31, 2025 5,674 $ 1 317,902 (312,229)
Balance at the beginning (in shares) at Mar. 31, 2025   8,495,000    
Issuance of common stock upon warrant exercise, (in share)   68,000    
Issuance of common stock upon warrant exercise 677   677  
Issuance costs for the 2025 PIPE (38)   (38)  
Stock Issued During Period Value Employee Stock Purchase Plan 61   61  
Stock Issued During Period Shares Employee Stock Purchase Plans   7,000    
Stock-based compensation expense 994   994  
Net (loss) income 39,746     39,746
Balance at the end at Jun. 30, 2025 47,114 $ 1 319,596 (272,483)
Balance at the end (in shares) at Jun. 30, 2025   8,570    
Balance at the beginning at Dec. 31, 2025 (187,762) $ 1 339,522 (527,285)
Balance at the beginning (in shares) at Dec. 31, 2025   9,775,000    
Issuance of common stock in the 2025 PIPE   1,400,000    
Issuance of common stock in a private placement 26,858   26,858  
Issuance of common stock upon warrant exercise, (in share)   289,000    
Issuance of common stock upon warrant exercise 8,065   8,065  
Vesting of restricted stock units   18,000    
Issuance of common stock upon option exercises 92   92  
Issuance of common stock upon option exercises, shares   8,000    
Stock-based compensation expense 2,105   2,105  
Net (loss) income (127,505)     (127,505)
Balance at the end at Mar. 31, 2026 (278,147) $ 1 376,642 (654,790)
Balance at the end (in shares) at Mar. 31, 2026   11,490,000    
Balance at the beginning at Dec. 31, 2025 $ (187,762) $ 1 339,522 (527,285)
Balance at the beginning (in shares) at Dec. 31, 2025   9,775,000    
Issuance of common stock upon option exercises, shares 14,000      
Net (loss) income $ (77,328)      
Balance at the end at Jun. 30, 2026 (218,665) $ 1 385,947 (604,613)
Balance at the end (in shares) at Jun. 30, 2026   11,754    
Balance at the beginning at Mar. 31, 2026 (278,147) $ 1 376,642 (654,790)
Balance at the beginning (in shares) at Mar. 31, 2026   11,490,000    
Issuance of common stock upon warrant exercise, (in share)   191,000    
Issuance of common stock upon warrant exercise 6,107   6,107  
Vesting of restricted stock units   46,000    
Issuance of common stock upon option exercises 91   91  
Stock Issued During Period Value Employee Stock Purchase Plan 214   214  
Issuance of common stock upon option exercises, shares   6,000    
Stock Issued During Period Shares Employee Stock Purchase Plans   21,000    
Stock-based compensation expense 2,893   2,893  
Net (loss) income 50,177     50,177
Balance at the end at Jun. 30, 2026 $ (218,665) $ 1 $ 385,947 $ (604,613)
Balance at the end (in shares) at Jun. 30, 2026   11,754